A New Form of Convolution Theorem for One-Dimensional Quaternion Linear Canonical Transform and Application
Symmetry · 26.06.2025 · 17 (7) · 1004
DOI: 10.3390/sym17071004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Symmetry, online erschienen am 26.06.2025. Verfasst von Mawardi Bahri und 4 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
In this research work, we focus on the one-dimensional quaternion linear canonical transform (1-D QLCT). Under certain conditions, we first derive the symmetry property of the 1-D QLCT for real signals. The new form of the convolution theorem related to this transformation is proposed. We develop this convolution definition to derive the correlation theorem for the 1-D QLCT. We then show that the direct connection between the quaternion convolution and quaternion correlation definitions permits us to provide a different way for proving the correlation theorem concerning the 1-D QLCT. Finally, we present a simple application of the convolution theorem to the study of quaternion swept-frequency filter analysis.
Zitieren
APA
Bahri, M., Karim, S. A. A., S., B. A., Nur, M., & Nurwahidah, N. (2025). A New Form of Convolution Theorem for One-Dimensional Quaternion Linear Canonical Transform and Application. Symmetry, 17(7), 1004. https://doi.org/10.3390/sym17071004
Vancouver
Bahri M, Karim SAA, S. BA, Nur M, Nurwahidah N. A New Form of Convolution Theorem for One-Dimensional Quaternion Linear Canonical Transform and Application. Symmetry. 2025;17(7):1004. doi:10.3390/sym17071004
BibTeX
@article{Bahri2025,
author = {Bahri, Mawardi and Karim, Samsul Ariffin Abdul and S., Bannu Addul and Nur, Muhammad and Nurwahidah, Nurwahidah},
title = {A New Form of Convolution Theorem for One-Dimensional Quaternion Linear Canonical Transform and Application},
journal = {Symmetry},
year = {2025},
volume = {17},
number = {7},
pages = {1004},
doi = {10.3390/sym17071004}
}
EUVIMED